Moreover, PECAM-1 could be considered as a potential therapeutic target for protecting the CNS from the cytotoxicity exerted by the immune cells and preventing the sustained cognitive impairment observed in conjunction with brain atrophy, even later than 6 months after surgery [28,29]. The gene discussed is PECAM1; the disease is Brain atrophy.